Form 4: Immunocore Holdings Executive Granted Stock Options and Restricted Share Units

Tina Amber St Leger, Chief HR Officer of Immunocore Holdings plc, received stock options and restricted share units (RSUs) on February 17, 2025, according to a Form 4 filing with the SEC.

Summary

• Tina Amber St Leger, the Chief HR Officer of Immunocore Holdings plc, was granted stock options and restricted share units (RSUs) on February 17, 2025.
• The stock options grant covers 23,212 ordinary shares with an exercise price of $29.60.
• 25% of the options will vest on February 17, 2026, with the remaining 75% vesting in quarterly installments thereafter, contingent upon continuous service.
• The options expire on February 16, 2035.
• Additionally, 8,476 RSUs were granted, each representing a contingent right to receive one ordinary share.
• These RSUs vest in four equal annual installments beginning February 17, 2026, also subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity compensation is a standard practice and suggests confidence in the company's future prospects. However, it doesn't provide any concrete information about the company's financial performance or strategic direction.

Positives

• The grant of stock options and RSUs to a key executive like the Chief HR Officer aligns her interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize long-term commitment and performance.

Risks

• The value of the stock options is dependent on the future performance of Immunocore Holdings' stock price.
• If St Leger leaves the company before the options and RSUs fully vest, she will forfeit the unvested portion.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued growth and value creation.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract, retain, and incentivize key employees. These grants align the interests of management with those of shareholders, encouraging long-term value creation.

Comparison to Industry Standards

• Equity compensation is a standard practice among publicly traded biotechnology companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and grant sizes are generally comparable to industry norms, designed to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: The equity grants align management's interests with those of shareholders, potentially leading to increased value.
• Employees: The grants can boost employee morale and incentivize performance.
• Executives: The grants provide a financial incentive for executives to drive the company's success.

Key Dates